EGRX Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Company profile
Ticker
EGRX
Exchange
Website
CEO
Scott Tarriff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EAGLE PHARMACEUTICALS INC
SEC CIK
Corporate docs
EGRX stock data
()
News
Eagle Pharmaceuticals: Q4 Earnings Insights
2 Mar 21
Earnings Scheduled For March 2, 2021
2 Mar 21
Earnings Preview: Eagle Pharmaceuticals
1 Mar 21
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
27 Feb 21
FDA Rejects Eagle Pharma's Vasopressin Application
2 Feb 21
Press releases
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review
2 Mar 21
Eagle Pharmaceuticals, Inc. to Host Earnings Call
2 Mar 21
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021
22 Feb 21
Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial
2 Feb 21
Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed
1 Feb 21
Investment data
Securities sold
Number of investors
Calendar
5 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.16M | 103.16M | 103.16M | 103.16M | 103.16M | 103.16M |
Cash burn (monthly) | (positive/no burn) | 551.67K | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | n/a | 1.9M | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 101.25M | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 183.5 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 21 | Steven B Ratoff | Common Stock | Option exercise | Aquire M | No | No | 4.42 | 2,340 | 10.34K | 27,364 |
8 Apr 21 | Steven B Ratoff | Common Stock | Option exercise | Aquire M | No | No | 8.78 | 2,340 | 20.55K | 25,024 |
8 Apr 21 | Steven B Ratoff | Common Stock | Option exercise | Aquire M | No | No | 8.78 | 2,340 | 20.55K | 22,684 |
8 Apr 21 | Steven B Ratoff | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.42 | 2,340 | 10.34K | 0 |
8 Apr 21 | Steven B Ratoff | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.78 | 2,340 | 20.55K | 0 |
8 Apr 21 | Steven B Ratoff | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.78 | 2,340 | 20.55K | 0 |
1 Apr 21 | Scott Tarriff | Common Stock | Payment of exercise | Dispose F | No | No | 41.87 | 16,278 | 681.56K | 1,544,906 |
1 Apr 21 | Scott Tarriff | Common Stock | Option exercise | Aquire M | No | No | 8.78 | 31,201 | 273.94K | 1,561,184 |
1 Apr 21 | Scott Tarriff | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.78 | 31,201 | 273.94K | 0 |
23 Feb 21 | Scott Tarriff | Common Stock | Gift | Dispose G | No | No | 0 | 16,340 | 0 | 1,529,983 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 166 |
Opened positions | 19 |
Closed positions | 22 |
Increased positions | 50 |
Reduced positions | 69 |
13F shares |
Current |
---|---|
Total value | 969.1M |
Total shares | 13.32M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 1.94M | $90.39M |
JHG Janus Henderson | 1.69M | $78.89M |
Scott Tarriff | 992.62K | $46.23M |
STT State Street | 814.1K | $37.91M |
Park West Asset Management | 791.6K | $36.87M |
Vanguard | 764.94K | $35.62M |
Armistice Capital | 364K | $16.95M |
IVZ Invesco | 311.63K | $14.51M |
Dimensional Fund Advisors | 307.01K | $14.3M |
Brandes Investment Partners | 264.4K | $12.3M |
Financial report summary
?Risks
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- If we cannot sustain profitability, our business, prospects, operating results and financial condition would be materially harmed.
- If we fail to obtain additional financing, we could be forced to delay, reduce or eliminate our product development programs.
- We may sell additional equity or incur debt to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on
- We cannot give any assurance that we will receive regulatory approval for our product candidates, which is necessary before they can be commercialized.
- If we are unable to differentiate our products or product candidates from branded reference drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the ability to successfully commercialize our product candidates would be adversely affected.
- If the FDA does not conclude that our product candidates satisfy the requirements for the regulatory approval, or if the requirements for approval of any of our product candidates are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.
- Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development.
- Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and could jeopardize or delay our ability to obtain regulatory approval and commence product sales. We may also find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our product candidates.
- Our products or product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance, or result in significant negative consequences following marketing approval, if any.
- The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
- An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidates.
- The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
- Our business is subject to extensive regulatory requirements and our approved product and product candidates that obtain regulatory approval will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products.
- Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- Any relationships with health care professionals, principal investigators, consultants, customers (actual and potential) and third party payors, in addition to our general business operations, are and will continue to be subject, directly or indirectly, to federal and state health care fraud and abuse laws, marketing expenditure tracking and disclosure, or sunshine laws, government price reporting and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties, including, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, integrity obligations, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.
- We are required to obtain regulatory approval for each of our products in each jurisdiction in which we intend to market such products, and the inability to obtain such approvals would limit our ability to realize their full market potential.
- If we fail to develop, acquire or in-license other product candidates or products, our business and prospects will be limited.
- Our commercial success depends upon attaining significant market acceptance of our products and product candidates, if approved, among physicians, nurses, pharmacists, patients and the medical community.
- Guidelines and recommendations published by government agencies can reduce the use of our products and product candidates.
- If we are unable to successfully conduct our sales and marketing capabilities or if our commercial partners do not adequately perform, the commercial opportunity for our products may be diminished.
- A substantial portion of our total revenues is derived from sales of a limited number of products.
- If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
- We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
- We could incur substantial costs and disruption to our business and delays in the launch of our product candidates if our competitors and/or collaborators bring legal actions against us, which could harm our business and operating results.
- If we are unable to achieve and maintain adequate levels of coverage and reimbursement for our products or product candidates, if approved, their commercial success may be severely hindered.
- Current and future legislation may increase the difficulty and cost for us to commercialize our product candidates and affect the prices we may obtain for our products.
- We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
- If any of our current strategic collaborators fail to perform their obligations or terminate their agreements with us, the development and commercialization of the product candidates under such agreements could be delayed or terminated and our business could be substantially harmed.
- We rely on third parties to manufacture commercial supplies of our products and clinical supplies of our product candidates, and we intend to rely on third parties to manufacture commercial supplies of any other approved products. The commercialization of any of our products could be stopped, delayed or made less profitable if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices or fail to maintain or achieve satisfactory regulatory compliance.
- The design, development, manufacture, supply, and distribution of our products and product candidates is highly regulated and technically complex.
- We rely on limited sources of supply for our products and product candidates, and any disruption in the chain of supply may impact production and sales of our products and cause delay in developing and commercializing our product candidates.
- We may not be successful in establishing development and commercialization collaborations which could adversely affect, and potentially prohibit, our ability to develop our product candidates.
- We may not be successful in maintaining development and commercialization collaborations, and any partner may not devote sufficient resources to the development or commercialization of our product candidates or may otherwise fail in development or commercialization efforts, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.
- If we are unable to maintain our group purchasing organization, ("GPO"), relationships, our revenues could decline and future profitability could be jeopardized.
- We rely on a limited number of pharmaceutical wholesalers to distribute our products.
- Our approved products may not achieve expected levels of market acceptance.
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
- We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.
- We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
- Business interruptions could delay us in the process of developing our product candidates and could disrupt our sales of any products we may sell.
- We may be constrained by our obligations under our Credit Agreement to operate our business to its full potential.
- If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.
- Our drug development strategy relies heavily upon the 505(b)(2) regulatory pathway, which requires us to certify that we do not infringe upon third-party patents covering approved drugs. Such certifications typically result in third-party claims of intellectual property infringement, the defense of which will be costly and time consuming, and an unfavorable outcome in any litigation may prevent or delay our development and commercialization efforts which would harm our business.
- If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.
- The patents and the patent applications that we have covering our products are limited to specific formulations, methods of use and processes, and our market opportunity for our products and our product candidates may be limited by the lack of patent protection for the active ingredients and by competition from other formulations and delivery methods that may be developed by competitors.
- Ryanodex® (dantrolene sodium), Belrapzo, and Bendeka ® among other products have been approved by the FDA, and we anticipate that other product candidates will be approved by the FDA in the future. Once our products are on the market, one or more third parties may also challenge the patents that we control covering our products, which could result in the invalidation or unenforceability of some or all of the relevant patent claims of our issued patents covering our products. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
- We have incurred significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.
- Future issuances of our common stock or rights to purchase our common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
- We are at risk of securities class action and similar litigation.
- We do not intend to pay cash dividends on our common stock so any returns will be limited to the value of our stock.
- There is no assurance that our Share Repurchase Program will result in repurchases of our common stock or enhance long term stockholder value.
- Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.
- Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Management Discussion
- Product sales decreased $1.7 million in the year ended December 31, 2020, primarily driven by decreases in product sales of Bendeka of $15.7 million coupled with decreases in Belrapzo’s product sales of $2.1 million primarily due to volume decreases. In addition, the COVID-19 pandemic and associated lockdowns have resulted in a decrease in healthcare utilization broadly and specifically have led to a reduction in the utilization of physician-administered oncology products including Belrapzo and Bendeka. The decreased sales were partially offset by increases in product sales of Ryanodex of $15.2 million due to higher volume coupled with product sales of $0.9 million from the 2020 product launch of Treakisym.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absenteeism, affiliated, aggressive, ahead, Aid, ameliorate, arbitration, arm, ascertain, Aurobindo, Azar, banc, Biden, bound, Brian, burden, Cahill, California, carryback, certiorari, circumstance, civilian, COBRA, CRL, departure, developmental, diffuse, distancing, economy, en, enjoining, entertainment, Ernst, Eugia, expert, explicitly, FedEx, flagged, formatted, hawse, hedge, hedging, heightened, heightening, home, implicitly, Importantly, indefinitely, indirect, Inline, insignificant, Instruction, Interactive, Interbank, intermuscular, isolation, iXBRL, Judith, length, lifting, London, Magistrate, magnitude, movement, nationwide, Northern, nurse, orTPIG, outbreak, pandemic, panel, partnership, ph, PMDA, polypeptide, postal, postpone, postponed, precaution, prioritization, prioritized, procurement, proficiency, refundable, refunded, rehearing, reinstated, resell, residence, resigned, resume, reward, ryanodine, ScinoPharm, shelter, Shilpa, Similarly, slowdown, spread, Taiwan, temporarily, tie, timeframe, timeline, titled, Trump, underway, unemployment, unnecessary, unopened, unprescribed, unrealized, urgently, vacation, vi, Vice, virtual, visibility, visit, visiting, weekly, withdrew, writ, Young
Removed:
accelerating, acceleration, acclimatization, accomplished, accretion, achievability, addressable, addressing, adenocarcinoma, adulterated, aggregated, bill, biosimilar, bivalirudin, Burwell, caption, cautioned, college, coma, commissioned, consisted, consult, contaminated, converting, cooling, core, correlated, counterfeit, dehydration, delirium, deliverable, die, disclaim, dissipate, diverted, divested, divided, dysfunction, electronically, emerge, essentially, eventually, exercising, exhaustive, factor, fast, FDIC, feasibility, flat, freely, functional, gastric, geographical, Hajj, head, humid, ice, identification, identifier, immersion, incomplete, inquiry, intentionally, logo, marginal, marking, minimal, modifying, muscular, neck, NOL, notification, offshore, optimize, organ, overhead, peak, phased, pilgrimage, preceding, Predisposing, Presidential, principally, probabilistic, proposal, provisional, ratably, recently, remeasured, renamed, repatriated, repealing, restriction, revaluation, reversed, revising, SAB, scheduling, seemingly, seller, simultaneously, skin, step, stolen, sudden, suggest, surface, symptomatic, territorial, thought, thousand, top, tracing, tradable, Unaudited, unduly, unfit, urge, utilized, validated, variability, verification, verify, warm, worth
Financial reports
10-K
2020 FY
Annual report
5 Mar 21
10-Q
2020 Q3
Quarterly report
2 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
2 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
Current reports
8-K
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review
2 Mar 21
8-K
Departure of Directors or Certain Officers
8 Feb 21
8-K
Other Events
2 Feb 21
8-K
Other Events
1 Feb 21
8-K
Regulation FD Disclosure
13 Jan 21
8-K/A
Departure of Directors or Certain Officers
28 Dec 20
8-K
Eagle Pharmaceuticals Reports Third Quarter 2020 Results
2 Nov 20
8-K
Changes in Registrant's Certifying Accountant
1 Oct 20
8-K
Regulation FD Disclosure
28 Sep 20
8-K
Regulation FD Disclosure
24 Sep 20
Registration and prospectus
S-3
Shelf registration
15 Nov 19
S-8
Registration of securities for employees
18 Dec 18
S-8
Registration of securities for employees
19 Mar 17
D
$50.74M in equity, sold $2.74M, 2 investors
22 Nov 16
S-8
Registration of securities for employees
15 Sep 16
S-8
Registration of securities for employees
1 Sep 15
424B5
Prospectus supplement for primary offering
16 Mar 15
424B5
Prospectus supplement for primary offering
15 Mar 15
S-3
Shelf registration
5 Mar 15
S-8
Registration of securities for employees
20 Feb 14
Proxies
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 17
DEF 14A
Definitive proxy
27 Apr 17
DEF 14A
Definitive proxy
11 Jul 16
Other
UPLOAD
Letter from SEC
20 Feb 20
CORRESP
Correspondence with SEC
28 Jan 20
UPLOAD
Letter from SEC
22 Dec 19
EFFECT
Notice of effectiveness
17 Dec 19
CORRESP
Correspondence with SEC
11 Dec 19
CORRESP
Correspondence with SEC
3 Dec 19
UPLOAD
Letter from SEC
21 Nov 19
CT ORDER
Confidential treatment order
21 Dec 17
UPLOAD
Letter from SEC
20 Feb 17
CORRESP
Correspondence with SEC
15 Feb 17
Ownership
4
EAGLE PHARMACEUTICALS / STEVEN B RATOFF ownership change
12 Apr 21
4
EAGLE PHARMACEUTICALS / STEVEN B RATOFF ownership change
7 Apr 21
4
EAGLE PHARMACEUTICALS / Scott Tarriff ownership change
5 Apr 21
SC 13G/A
EAGLE PHARMACEUTICALS / Tarriff Scott ownership change
16 Feb 21
SC 13G/A
EAGLE PHARMACEUTICALS / ARMISTICE CAPITAL ownership change
16 Feb 21
SC 13G/A
EAGLE PHARMACEUTICALS / Park West Asset Management ownership change
15 Feb 21
SC 13G/A
EAGLE PHARMACEUTICALS / JANUS HENDERSON ownership change
11 Feb 21
SC 13G/A
EAGLE PHARMACEUTICALS / VANGUARD ownership change
9 Feb 21
SC 13G
EAGLE PHARMACEUTICALS / STATE STREET ownership change
8 Feb 21
4
EAGLE PHARMACEUTICALS / Jennifer K. Simpson ownership change
4 Feb 21
Patents
APP
Utility
Liquid Protein Formulations Containing Viscosity-Lowering Agents
25 Mar 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
APP
Utility
Liquid Protein Formulations Containing Organophosphates
11 Feb 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
APP
Utility
Liquid Protein Formulations Containing Ionic Liquids
4 Feb 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
APP
Utility
Methods of Using Dantrolene to Treat Nerve Agent Exposure
9 Dec 20
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.
GRANT
Utility
Liquid Protein Formulations Containing Thiamine
30 Nov 20
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Transcripts
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q2
Earnings call transcript
10 Aug 20
2020 Q1
Earnings call transcript
11 May 20
2019 Q4
Earnings call transcript
2 Mar 20
2019 Q3
Earnings call transcript
12 Nov 19
2019 Q2
Earnings call transcript
9 Aug 19
2019 Q1
Earnings call transcript
7 May 19